APTEVO THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3129 USD | -5.47% |
|
+7.19% | -96.07% |
| Jul. 01 | Aptevo Therapeutics Inc. announced that it has received $2.75 million in funding | CI |
| Jun. 28 | Aptevo Shares Decline After Pricing of $2.8 Million Stock Offering | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 29.64 | 160.5 | 38.55 | 11.81 | 3.41 | 4.081 | - | - |
| Enterprise Value (EV) 1 | 29.64 | 160.5 | 38.55 | 11.81 | 3.41 | 4.081 | 4.081 | 4.081 |
| P/E ratio | -0.66 x | -7.01 x | -1.3 x | 1.48 x | -0.13 x | -0.04 x | -0.05 x | -0.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.91 x | 37.2 x | 3.14 x | 3.79 x | - | - | - | 0.31 x |
| EV / Revenue | 0.91 x | 37.2 x | 3.14 x | 3.79 x | - | - | - | 0.31 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 73.5 | 99.5 | 111 | 116 | 428 | 13,042 | - | - |
| Reference price 2 | 403.2 | 1,613 | 346.3 | 102.1 | 7.964 | 0.3129 | 0.3129 | 0.3129 |
| Announcement Date | 3/25/20 | 3/31/21 | 3/24/22 | 3/30/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 32.42 | 4.309 | 12.29 | 3.114 | - | - | - | 13.22 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -42.6 | -27.49 | -21.4 | -28.64 | -28.88 | -28.14 | -31.3 | -18.57 |
| Operating Margin | -131.37% | -638.06% | -174.1% | -919.75% | - | - | - | -140.51% |
| Earnings before Tax (EBT) 1 | -44.7 | -30.92 | -29.41 | 7.014 | -18.65 | -27.99 | -31.3 | -18.57 |
| Net income 1 | -40.45 | -17.75 | -28.46 | 8.027 | -17.41 | -27.99 | -31.3 | -18.57 |
| Net margin | -124.75% | -411.93% | -231.51% | 257.77% | - | - | - | -140.51% |
| EPS 2 | -609.8 | -230.1 | -267.1 | 69.08 | -62.48 | -8.860 | -5.770 | -3.260 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/25/20 | 3/31/21 | 3/24/22 | 3/30/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.665 | 3.114 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.04 | -5.611 | -7.562 | -7.784 | -7.684 | -7.756 | -8.178 | -6.561 | -6.384 | -6.983 | -7.018 | -7.053 | -7.088 |
| Operating Margin | -110.23% | -180.19% | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.597 | -7.875 | 27.86 | -7.809 | -5.163 | 1.827 | -7.948 | -6.334 | -6.196 | -6.834 | -7.018 | -7.053 | -7.088 |
| Net income 1 | -6.272 | -7.697 | 28.01 | -7.644 | -4.642 | 2.773 | -7.948 | -6.334 | -5.903 | -6.834 | -7.018 | -7.053 | -7.088 |
| Net margin | -171.13% | -247.17% | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -55.88 | -68.20 | 245.5 | -66.00 | -41.80 | 17.16 | -54.12 | -22.00 | -6.160 | -9.950 | -1.930 | -1.710 | -1.700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/5/24 | 5/8/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/25/20 | 3/31/21 | 3/24/22 | 3/30/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3129
USD
Average target price
748
USD
Spread / Average Target
+238,953.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -96.07% | 2.41M | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- APVO Stock
- Financials Aptevo Therapeutics Inc.
